Programmatic Research Supported

Breast cancer trials included in II/ACRIN reflects a cooperative effort between the University of Alabama at Birmingham (UAB) and the University of Michigan. For the year 2023, $3,054 was spent with sunitinib.

Tumor metrics reports generated by study personnel to provide service. The images below demonstrate favorable treatment outcomes for patients with breast cancer.

Patient with gastrointestinal stromal tumor being treated with sunitinib on an investigatinitiated clinical trial (UAB 8555, J. Posey MD-ET). Color maps of k trans, k ep and apparent diffusion coefficient (ADC) demonstrate whole tumor early therapeutic and six week responses. Imaging Biomarker post processing performed by CCC member H. Kim PhD (ET).

Different patients with breast cancer (left) participating in UAB 1367 (C. Vaklavas MD-ET), lymphoma (center) participating in UAB 1461 (A. Forero MD-ET) and pancreas ductal adenocarcinoma (right) participating in UAB 1480 (J. Posey MD-ET). All show favorable response on surveillance imaging, whether anatomic, physiologic, or both.

EXAMPLES OF TUMOR METRICS REPORTS:

Rationale and Value-Added

- Effective, timely support of imaging services for clinical trials
- Development of novel approaches to response assessment
- Protocol reviews and FAP assistance
- Identify non-routine imaging techniques and ensure protocol specific constraints are met
- Tumor metrics reports generated by study-dedicated expert reader longitudinally throughout entire trial
- Web based tracking of protocols for Radiology personnel to provide service

Programmatic Usage

EXAMPLE: Advanced Imaging Biomarkers

EXAMPLES: Standard Clinical Trials supported by HISF

EXAMPLES: Cooperative Group and Investigator Initiated Trials supported by HISF

GOALS:
- Perform standardized protocol review
- Provide state-of-the-art imaging acquisition
- Perform standardized tumor metrics quantification and response assessment
- Develop and implement new analysis tools and techniques

Service and Operation

Objectives:

- Services and Operation
- Programmatic Research Supported

Programmatic Research Supported

Human Imaging Shared Facility

Janet F. Eary MD, Facility Co-Director
Desiree E. Morgan, MD, Facility Co-Director

Operating Costs and Budget

Operating Costs and Budget

Current CCSG Budget

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>$150,422</td>
</tr>
<tr>
<td>Supplies</td>
<td>$3,064</td>
</tr>
<tr>
<td>Other</td>
<td>$6,824</td>
</tr>
<tr>
<td>Total</td>
<td>$160,000</td>
</tr>
</tbody>
</table>

Current Operating Costs

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charge Backs</td>
<td>61%</td>
</tr>
<tr>
<td>CCSG</td>
<td>30%</td>
</tr>
<tr>
<td>Other</td>
<td>9%</td>
</tr>
</tbody>
</table>

Future Plans

SHORT TERM:
- Pilot integrated metrics reports for phase 1 program and expand to all trials in future

LONG TERM:
- Enhance biomarker and post-processing support
- Generate novel PET imaging and therapeutic agent response strategies (to complement cyclotron and AIF)

CYCLOTRON and AIF:

Facility Director: Janet F Eary, MD
Medical Imaging Research

Kurt Zinn, DVM, MS, Ph.D.

Radiopharmacy

Janie Par, PhD

Radiopharmaceuticals

Charlotte Denise Jeffers, BS/Pharm, RPPh

Engineering Manager

Harvey McConathy, BSPharm

Administration

Morgan Aminos

Scientifica

Robert Keeler, MD, neuroradiology

Jonathan E. Morgan, MD, radiology imaging

Protocol reviews and FAP assistance

Operating Costs and Budget

Operating Costs and Budget

Current CCSG Budget

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>$150,422</td>
</tr>
<tr>
<td>Supplies</td>
<td>$3,064</td>
</tr>
<tr>
<td>Other</td>
<td>$6,824</td>
</tr>
<tr>
<td>Total</td>
<td>$160,000</td>
</tr>
</tbody>
</table>

Current Operating Costs

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charge Backs</td>
<td>61%</td>
</tr>
<tr>
<td>CCSG</td>
<td>30%</td>
</tr>
<tr>
<td>Other</td>
<td>9%</td>
</tr>
</tbody>
</table>

Future Plans

SHORT TERM:
- Pilot integrated metrics reports for phase 1 program and expand to all trials in future

LONG TERM:
- Enhance biomarker and post-processing support
- Generate novel PET imaging and therapeutic agent response strategies (to complement cyclotron and AIF)

CYCLOTRON and AIF:

Facility Director: Janet F Eary, MD
Medical Imaging Research

Kurt Zinn, DVM, MS, Ph.D.

Radiopharmacy

Janie Par, PhD

Radiopharmaceuticals

Charlotte Denise Jeffers, BS/Pharm, RPPh

Engineering Manager

Harvey McConathy, BSPharm

Administration

Morgan Aminos

Scientifica

Robert Keeler, MD, neuroradiology

Jonathan E. Morgan, MD, radiology imaging

Protocol reviews and FAP assistance

Operating Costs and Budget

Operating Costs and Budget

Current CCSG Budget

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>$150,422</td>
</tr>
<tr>
<td>Supplies</td>
<td>$3,064</td>
</tr>
<tr>
<td>Other</td>
<td>$6,824</td>
</tr>
<tr>
<td>Total</td>
<td>$160,000</td>
</tr>
</tbody>
</table>

Current Operating Costs

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charge Backs</td>
<td>61%</td>
</tr>
<tr>
<td>CCSG</td>
<td>30%</td>
</tr>
<tr>
<td>Other</td>
<td>9%</td>
</tr>
</tbody>
</table>

Future Plans

SHORT TERM:
- Pilot integrated metrics reports for phase 1 program and expand to all trials in future

LONG TERM:
- Enhance biomarker and post-processing support
- Generate novel PET imaging and therapeutic agent response strategies (to complement cyclotron and AIF)

CYCLOTRON and AIF:

Facility Director: Janet F Eary, MD
Medical Imaging Research

Kurt Zinn, DVM, MS, Ph.D.

Radiopharmacy

Janie Par, PhD

Radiopharmaceuticals

Charlotte Denise Jeffers, BS/Pharm, RPPh

Engineering Manager

Harvey McConathy, BSPharm

Administration

Morgan Aminos

Scientifica

Robert Keeler, MD, neuroradiology

Jonathan E. Morgan, MD, radiology imaging

Protocol reviews and FAP assistance

Operating Costs and Budget

Operating Costs and Budget

Current CCSG Budget

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>$150,422</td>
</tr>
<tr>
<td>Supplies</td>
<td>$3,064</td>
</tr>
<tr>
<td>Other</td>
<td>$6,824</td>
</tr>
<tr>
<td>Total</td>
<td>$160,000</td>
</tr>
</tbody>
</table>

Current Operating Costs

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charge Backs</td>
<td>61%</td>
</tr>
<tr>
<td>CCSG</td>
<td>30%</td>
</tr>
<tr>
<td>Other</td>
<td>9%</td>
</tr>
</tbody>
</table>

Future Plans

SHORT TERM:
- Pilot integrated metrics reports for phase 1 program and expand to all trials in future

LONG TERM:
- Enhance biomarker and post-processing support
- Generate novel PET imaging and therapeutic agent response strategies (to complement cyclotron and AIF)

CYCLOTRON and AIF:

Facility Director: Janet F Eary, MD
Medical Imaging Research

Kurt Zinn, DVM, MS, Ph.D.

Radiopharmacy

Janie Par, PhD

Radiopharmaceuticals

Charlotte Denise Jeffers, BS/Pharm, RPPh

Engineering Manager

Harvey McConathy, BSPharm

Administration

Morgan Aminos

Scientifica

Robert Keeler, MD, neuroradiology

Jonathan E. Morgan, MD, radiology imaging

Protocol reviews and FAP assistance

Operating Costs and Budget

Operating Costs and Budget

Current CCSG Budget

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>$150,422</td>
</tr>
<tr>
<td>Supplies</td>
<td>$3,064</td>
</tr>
<tr>
<td>Other</td>
<td>$6,824</td>
</tr>
<tr>
<td>Total</td>
<td>$160,000</td>
</tr>
</tbody>
</table>

Current Operating Costs

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charge Backs</td>
<td>61%</td>
</tr>
<tr>
<td>CCSG</td>
<td>30%</td>
</tr>
<tr>
<td>Other</td>
<td>9%</td>
</tr>
</tbody>
</table>

Future Plans

SHORT TERM:
- Pilot integrated metrics reports for phase 1 program and expand to all trials in future

LONG TERM:
- Enhance biomarker and post-processing support
- Generate novel PET imaging and therapeutic agent response strategies (to complement cyclotron and AIF)

CYCLOTRON and AIF:

Facility Director: Janet F Eary, MD
Medical Imaging Research

Kurt Zinn, DVM, MS, Ph.D.

Radiopharmacy

Janie Par, PhD

Radiopharmaceuticals

Charlotte Denise Jeffers, BS/Pharm, RPPh

Engineering Manager

Harvey McConathy, BSPharm

Administration

Morgan Aminos

Scientifica

Robert Keeler, MD, neuroradiology

Jonathan E. Morgan, MD, radiology imaging

Protocol reviews and FAP assistance

Operating Costs and Budget

Operating Costs and Budget

Current CCSG Budget

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>$150,422</td>
</tr>
<tr>
<td>Supplies</td>
<td>$3,064</td>
</tr>
<tr>
<td>Other</td>
<td>$6,824</td>
</tr>
<tr>
<td>Total</td>
<td>$160,000</td>
</tr>
</tbody>
</table>

Current Operating Costs

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charge Backs</td>
<td>61%</td>
</tr>
<tr>
<td>CCSG</td>
<td>30%</td>
</tr>
<tr>
<td>Other</td>
<td>9%</td>
</tr>
</tbody>
</table>

Future Plans

SHORT TERM:
- Pilot integrated metrics reports for phase 1 program and expand to all trials in future

LONG TERM:
- Enhance biomarker and post-processing support
- Generate novel PET imaging and therapeutic agent response strategies (to complement cyclotron and AIF)

CYCLOTRON and AIF:

Facility Director: Janet F Eary, MD
Medical Imaging Research

Kurt Zinn, DVM, MS, Ph.D.

Radiopharmacy

Janie Par, PhD

Radiopharmaceuticals

Charlotte Denise Jeffers, BS/Pharm, RPPh

Engineering Manager

Harvey McConathy, BSPharm

Administration

Morgan Aminos

Scientifica

Robert Keeler, MD, neuroradiology

Jonathan E. Morgan, MD, radiology imaging

Protocol reviews and FAP assistance

Operating Costs and Budget

Operating Costs and Budget

Current CCSG Budget

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>$150,422</td>
</tr>
<tr>
<td>Supplies</td>
<td>$3,064</td>
</tr>
<tr>
<td>Other</td>
<td>$6,824</td>
</tr>
<tr>
<td>Total</td>
<td>$160,000</td>
</tr>
</tbody>
</table>

Current Operating Costs

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charge Backs</td>
<td>61%</td>
</tr>
<tr>
<td>CCSG</td>
<td>30%</td>
</tr>
<tr>
<td>Other</td>
<td>9%</td>
</tr>
</tbody>
</table>